Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT
This article was originally published in The Gray Sheet
Executive Summary
U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago
You may also be interested in...
Looking Off-Label: Drug-Eluting Stents Versus Surgery And Bare-Metal
Two registry studies reported last week assess outcomes from drug-eluting stent procedures in patients with conditions that are not approved indications for the device. In one, the stents did not match the outcomes of open-heart surgery, but in the other the devices outpeformed their bare-metal cousins
Looking Off-Label: Drug-Eluting Stents Versus Surgery And Bare-Metal
Two registry studies reported last week assess outcomes from drug-eluting stent procedures in patients with conditions that are not approved indications for the device. In one, the stents did not match the outcomes of open-heart surgery, but in the other the devices outpeformed their bare-metal cousins
Device Firms Go Direct To Consumers Amid Physician Skepticism
Device firms are increasing investments in television advertising for their implantable products, but some physicians are skeptical that safety information about complex devices can be adequately conveyed in direct-to-consumer ads